ReNeuron Group (ReNeuron Group) Change In Inventory

: $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2006. Start your Free Trial

ReNeuron Group's change in inventory for the quarter that ended in Sep. 2023 was $0.00 Mil. It means ReNeuron Group's inventory stayed the same from Mar. 2023 to Sep. 2023 .

ReNeuron Group's change in inventory for the fiscal year that ended in Mar. 2023 was $0.00 Mil. It means ReNeuron Group's inventory stayed the same from Mar. 2022 to Mar. 2023 .

ReNeuron Group's Total Inventories for the quarter that ended in Sep. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ReNeuron Group's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.00.

ReNeuron Group Change In Inventory Historical Data

The historical data trend for ReNeuron Group's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Inventory

Get a 7-Day Free Trial

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

ReNeuron Group Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

ReNeuron Group (OTCPK:RNUGF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ReNeuron Group's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ReNeuron Group's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ReNeuron Group's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.194
	=	0.00

ReNeuron Group Change In Inventory Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (ReNeuron Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

RENE.GB:UK RENE:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.